Orlando, Fla, March 06, 2018 --
March 2, 2018 – XYMOGEN, Inc., a leading manufacturer of medical foods and dietary supplements, announced today that is has prevailed in a lawsuit with Thorne Research. On February 20, 2018, after a six-day trial, a jury in the United States District Court for the District of Utah ruled for XYMOGEN. The jury found that XYMOGEN’s proprietary and highly-absorbed CoQMax product was actually invented by a chemist from XYMOGEN’s manufacturer thereby invalidating Thorne’s patent on their product.
|
|||
“I am extremely pleased that the jury saw fit to discredit Thorne’s claims and invalidate their patent”, said Brian Blackburn, XYMOGEN’s Founder and CEO. “Claiming a patent on an invention by a third-party misleads the public, and I hope the jury’s verdict will deter others from similar practices.”
About XYMOGEN:
To learn more about XYMOGEN, a family-owned, health sciences company, and its formulas, distribution, and community involvement, visit XYMOGEN.com, email pr@xymogen.com, or call 800-647-6100. XYMOPrint, a full-service digital printer and design studio, XYMOGEN LOGISTICS, a third-party fulfillment, warehousing, and shipping provider; and PharmaceutiX Medical Foods are all subsidiaries of XYMOGEN.
6900 Kingesporte Parkway
Orlando, Fl
Tel: 800-647-6100
info@xymogen.com
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a48371c-6283-4c53-afa1-bb7a889b35d1
Meghan Blackburn XYMOGEN 800-647-6100, Ext. 8875 Meghan.Blackburn@Xymogen.com
